Skip to main content
OpenTrials
Completed

NCT Number: NCT01458171

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06_002CR (NCT01199705).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Immune Deficiency Disorder Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Immune System Diseases Immunologic Deficiency Syndromes Primary Immunodeficiency Diseases

Age range

Up to 75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Study site, Nagoya, Aichi Pref., Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who have participated in study ZLB06_002CR and who have tolerated IgPro20 well.
  • Written informed consent by the subject/parent/legally acceptable representative. Written assent for an underage subject (≥7 years at the time of obtaining informed consent), as far as possible.

Exclusion criteria

  • Ongoing serious bacterial infections (SBIs) (pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of the first infusion.
  • Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (known total urine protein concentration >0.2 g/L or urine protein ++ by dipstick).
  • Pregnancy or nursing mother.
  • Participation in a study with an investigational medicinal product (IMP) within 3 months prior to enrollment except for ZLB06_002CR.
  • Subjects who are planning to donate blood during the study.
  • Re-entry of subjects previously participating in the current follow-up study.
  • Known or suspected antibodies to the IMP, or to excipients of the IMP.

Treatment and study plan

Immune globulin subcutaneous (Human)

Biological

IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).

Other names: Hizentra

Primary outcomes

  1. Median of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion

    Time frame: 24 weeks

    The rate was calculated by counting all newly developed or worsened AEs within a subject and dividing by the total number of IgPro20 infusions administered to this subject. Subsequently, the median of these individual AE rates per infusion was calculated. AE rates were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related [i.e., possibly related, probably related, or related]).

Secondary outcomes

  1. Overall Rate of AEs Per Infusion

    Time frame: 24 weeks

    The rate was calculated by counting all newly developed or worsened AEs during the treatment period in all subjects and dividing the total number of AEs by the total number of IgPro20 infusions administered. In addition, individual AEs were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related [i.e., possibly related, probably related, or related]). The AE rates per infusion by severity and causal relationship to study medication were calculated by dividing the number of AEs in each category by the total number of IgPro20 infusions.

  2. Number of Subjects With Newly Developing or Worsening AEs

    Time frame: 24 weeks

    Number of subjects with AEs, overall and classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related [i.e., possibly related, probably related, or related]).

  3. Percentage of Infusions With Subject-assessed Tolerability of at Least 'Good'

    Time frame: 24 to 72 hours after infusion

    Subjects assessed their overall perception of local tolerability at the infusion site throughout the study in the subject diary within a time window of 24 h to 72 h after the end of the latest infusion by assessing it as "very good", "good", "fair", or "poor". The reported percentage represents the percentage of subjects with local tolerability assessments of "very good" or "good" at any given study infusion.

  4. IgG Trough Level

    Time frame: 24 weeks

    Serum IgG trough levels at the completion visit compared to the baseline visit of the follow-up study. IgG trough levels at baseline, at the completion visit, and the change from baseline to the completion visit are shown

  5. Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)

    Time frame: 24 weeks

    SBIs are defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess. The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the FAS and PPS and adjusted to 365 days.

  6. Number of Infection Episodes (Serious and Non-serious)

    Time frame: 24 weeks

  7. Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections.

    Time frame: 24 weeks

    Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections.

  8. Number of Days of Hospitalization Due to Infections.

    Time frame: 24 weeks

    Median number of days of hospitalization due to infections.

  9. Duration of Use of Antibiotics for Infection Prophylaxis and Treatment

    Time frame: 24 weeks

    Median number of days of use of antibiotics for infection prophylaxis and/or treatment

Other outcomes

  1. Rate of Infection Episodes (Serious and Non-serious)

    Time frame: 24 weeks

    The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the FAS population and the PPS population and adjusted to 365 days.

Sponsors and collaborators

Lead sponsor

CSL Behring

Industry

Registry information

Official study title

A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Oct 24, 2011
Registry last updated
Apr 9, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.